Mitchell Levine

Mitchell Levine

Chairman chez IMMUNOPRECISE ANTIBODIES LTD.

Fortune : 30 400 $ au 31/03/2024

Finance
Health Technology
Consumer Services

Postes actifs de Mitchell Levine

SociétésPosteDébutFin
IMMUNOPRECISE ANTIBODIES LTD. Chairman 27/11/2023 -
Director/Board Member - 27/11/2023
Chief Executive Officer 01/11/2022 -
Chairman - -

Historique de carrière de Mitchell Levine

Anciens postes connus de Mitchell Levine

SociétésPosteDébutFin
Chief Investment Officer 01/01/2002 01/01/2017
Compliance Officer 01/01/2002 01/01/2017
Founder 27/07/2011 01/01/2017
Cove Capital Advisors, Inc. Corporate Officer/Principal - -
ONCOCYTE CORPORATION Director of Finance/CFO 15/11/2017 01/06/2022
Corporate Officer/Principal 01/06/2022 -
Lehman Brothers Distressed Structured Credit Capital Partners Corporate Officer/Principal - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -

Formation de Mitchell Levine

University of California, Davis Undergraduate Degree

Statistiques

Internationale

Etats-Unis 9
Canada 2

Opérationnelle

Corporate Officer/Principal 5
Chairman 2
Chief Investment Officer 1

Sectorielle

Finance 4
Health Technology 4
Consumer Services 2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés liées

Sociétés cotées2
ONCOCYTE CORPORATION

Health Technology

IMMUNOPRECISE ANTIBODIES LTD.

Health Technology

Entreprise privées6

Finance

Lehman Brothers Distressed Structured Credit Capital Partners

Finance

Finance

Cove Capital Advisors, Inc.

Health Technology

Voir les connexions sociétés